



A. Morphology



B. Trypan blue assay



C. FACS analysis

	G1	S	G2/M
T47D-Parental	50.06	20.00	29.94
T47D-shScramble	51.88	20.61	27.51
T47D-shLuc	52.36	18.02	29.62
T47D-shAbl-1	49.71	21.87	28.43
T47D-shAbl-2	54.14	21.41	24.46
BT474-shLuc	78.17	14.1	7.73
BT474-shAbl-1	74.41	15.9	9.69
BT474-shAbl-2	69.3	19.64	11.06

Figure W1. Morphology and growth characterization of T47D and BT474 cell clones used in the study. (A) Cell morphology under light microscope (5x amplification) of the cell lines indicated. (B) Cell viability determined by Trypan blue analysis. (C) Flow cytometry analysis for the cell cycle status of the indicated cell lines.

MCF-7 transfectants





Figure W2. MCF-7 cells transfected with the control vector (pcDNA3), or the cDNA of WT c-ABL (c-ABL/WT), or the kd (c-ABL/kd) c-ABL mutants as indicated in Figure 1. The cells were cultured for 3 days and subject to G418 selection (500 $\mu\text{g}/\text{ml}$) for 2 weeks to enrich the transfected cells. The pooled cell clones were then lysed, and the expression level of c-ABL and the endogenous level of tubulin were then determined by Western analysis.

A.



B.




Figure W3. Interaction between c-ABL and ER in BT474 cells. (A) ER and c-ABL are colocalized in BT474 cells by confocal immunofluorescence microscopy as described in Figure 5C. Arrows indicate examples of colocalization (yellow). (B) The interaction is enhanced by TAM treatment, which is demonstrated by immunoprecipitation of c-ABL as described in Figure 5D.




Figure W4. Targeting c-ABL activity sensitizes breast cancer cells to TAM treatment. (A) BT474 cells were treated with control vehicle alone (C) (white bars), 5 μ M of TAM (T) or 10 μ M imatinib (I) alone (gray bars), or in combination (black bars) as indicated, and the effect on cell growth was measured by the CellTiter-Glo kit (Promega). * $P < .05$ compared with TAM treatment alone. Similar results were obtained by MTT assays (data not shown). (B) A representative isobologram analysis of the TAM-imatinib combination in BT474 cells. The result indicates that in combination with 10 μ M of imatinib, the combination of TAM and imatinib yields either a synergistic or an additive activity.